CS1001
CS1001 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of CS1001 in Subjects with Advanced Solid Tumors
A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Clinical Trials (7)
A Study of CS1001 in Subjects with Advanced Solid Tumors
A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7